tumour-antigen-immune-35.html
Novo Annual Review 2016
36 / 71
private
com
panies acacia pharma focuses on the development
of compounds for the prevention and treatment of nausea and vomiting following surgery and chemotherapy. the lead programme is in phase 3 clinical development. www
.acaciapharma.com allakos develops monoclonal antibody-based therapies to target eosinophils and mast cells. the lead programme is in pre-clinical development. www.allakos.com anaptysbio is an antibody therapeutics company and a leader in antibody discovery and optimisation. www.anaptysbio.com anokion develops novel peptide and protein therapeutic with very low immunogenicity. the company is focused on products for orphan diseases. www.anokion.com battersea biotech develops alternative cell types and technologies to overcome the shortcomings of current car-t and tcr technologies. bolt therapeutics plans to develop a novel format for t-cell mediated anti-tumour therapy. cianna medical is a medical device company that manufactures and markets the savi breast brachytherapy applicator for the delivery of radiation after lumpectomy surgery. www.ciannamedical.com entasis therapeutics is a spin out from astra zeneca. the company is developing novel antibiotics for treatment of severe gram-negative infections. the focus is on developing new antibiotics to treat infections resistant to current treatments. www.entasistx.com epsilon-3 bio develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. the lead compound is in pre-clinical development. www.epsilon-3.com e-scape bio is developing a pipeline of apoe4 structure correctors for the treatment of neurodegenerative diseases, including alzheimer?s disease. f2g is focusing on the discovery and development of novel drugs to treat life-threatening fungal diseases. www.f2g.com galera therapeutics is a clinical-stage company focused on the development of highly selective small molecule dismutase mimetics, targeting the prevention of radiation-induced mucositis. www.galeratx.com kanyos bio is a spin out from anokion. the company has the rights to develop celiac disease and t1d autoimmune programmes and an option deal with astellas. www.kanyos.com karus therapeutics develops innovative therapies for the treatment of inflammation and cancer. the lead programmes are in pre-clinical development and focus on histone deacetylase and phosphoinositide 3-kinase inhibitors. www.karustherapeutics.com minerva surgical focuses on women?s healthcare. currently, minerva surgical?s development projects are aimed at delivering next generation products for the treatment of abnormal uterine bleeding. www.minervasurgical.com e-scape bio battersea biotech bolt therapeutics novo ventures portfolio companies 36 novo a/s 2016
com-www-treatment-37.html
